Background/Objectives: Melanoma in children and adolescents is uncommon, and
diagnosed later, are more likely to present with thicker tumors, and often have sentinel lymph node metastasis. 9, 10 Given these clinical differences, researchers have proposed that pediatric melanoma in very young children may be a distinct biologic entity. 7, 10 Adult-based protocols for treating pediatric melanoma may incur unnecessary morbidity in children if their disease follows a less aggressive disease course. Better characterization of pediatric melanoma is a crucial research priority with the potential to meaningfully affect patient management and patient counseling. In this study, more than 2 decades worth of data from children and adolescents with melanoma treated at Massachusetts General Hospital (MGH) in Boston, Massachusetts, are analyzed. MGH is a tertiary referral center with a full-service pediatric hospital, and the institution's Pigmented Lesion Clinic treated more than 3200 individuals during the last 7 years of the study period.
| MATERIALS AND METHODS
A retrospective cohort study design was used. After obtaining institu- analysis, patients were divided into two groups: childhood melanoma (children), which includes patients diagnosed before age 11, and adolescent melanoma (adolescents), which includes patients diagnosed at or after age 11 and before age 20; 11 was chosen in keeping with the literature as the age cut-off to separate prepubertal patients. 9, 11, 12 3 | RESULTS Thirty-two children with melanoma were identified ( Table 1) . Ages ranged from 3.3 to 19.5 years at time of diagnostic biopsy. There were 12 children and 20 adolescents, and median age at biopsy was 9.3 and 15.7 years, respectively. Median follow-up time for survivors in the full cohort was 3.6 years, with 80% of patients having more than 1.6 years of follow-up.
There were no significant differences between children and adolescents in sex, race, Fitzpatrick skin phototype, or tumor site (Table 2 ). Many melanomas in both groups demonstrated lesional evolution before biopsy (9 children, 14 adolescents), but very few patients presented with the following risk factors: first-degree family history of melanoma (0 children, 1 adolescent), previous blistering sunburn (0 children, 4 adolescents), indoor tanning activity (0 children, 2 adolescents), significant medical comorbidity (1 child, 0 adolescents), or predisposing skin lesion (1 child, 4 adolescents).
Children and adolescents had different melanoma subtypes. Children most commonly presented with spitzoid (n = 6), followed by in situ (n = 2), nodular (n = 2), superficial spreading (n = 1), and unclassified melanoma (n = 1). Adolescents most commonly presented with superficial spreading (n = 7), followed by in situ (n = 6), unclassified (n = 4), spitzoid (n = 2), and nodular melanoma (n = 1).
Spitzoid melanomas were significantly more common in children than adolescents (P = .01). In regards to predisposing lesions, one superficial spreading melanoma in a child developed in a medium congenital melanocytic nevus, two superficial spreading melanomas in adolescents developed in small congenital melanocytic nevi, one adolescent with a superficial spreading had an unrelated medium congenital melanocytic nevus, and one adolescent with an unclassified melanoma subtype presenting in the brain had a nevus of Ota.
Children tended to present at a more advanced histopathologic ). Children also were more likely to have neural invasion (Table 3) . Four patients experienced distant metastasis and died, all of whom were adolescents (20%) ( Figure 1 ). Survival curves were significantly different for adolescents and children based on the logrank test (P = .04, Figure 1 ). When patients were compared according to melanoma subtype, there was no significant survival difference (log-rank test P = .06, Figure 2 ). For both of these analyses, patients with melanoma in situ were excluded, because stage 0 melanoma does not carry a risk for metastasis.
| DISCUSSION
This study confirms previous observations that pediatric melanoma, particularly early childhood melanoma, is uncommon. Data from this These results support the hypothesis that melanoma in young children may be biologically distinct from melanoma in adults. Alternatively, melanoma subtype may drive survival differences between children and adolescents. Adolescents and children in this cohort had different subtype distributions, and children younger than 11
were significantly more likely to have spitzoid melanoma. A study by Carrera and colleagues corroborates the finding that, in children, spitzoid melanoma is associated with younger age than nonspitzoid melanoma. 13 Although our results did not demonstrate a significant difference in survival according to melanoma subtype, and a recent prospective study of pediatric melanoma demonstrated that spitzoid subtype does not confer a survival benefit over nonspitzoid melanoma, 14 larger studies are required to determine whether adolescents present with more aggressive melanoma subtypes than younger children.
Further research on outcomes for individuals with spitzoid melanoma is particularly important given that a subset of spitzoid tumors present histopathologic challenges. 15 For these cases, even expert dermatopathologists may have difficulty achieving consensus as to whether the tumors are atypical or outright malignant. 16 Histopathologic features that support a diagnosis of spitzoid melanoma include asymmetry, poor circumscription, ulceration, lack of Kamino bodies, lack of junctional clefting, dense cellularity, irregular nests with poor maturation, deep mitotic figures, heterogenous cell types, and specific nuclear characteristics. 17 At the time of this study, genomic tests had not proven helpful in distinguishing challenging spitzoid tumors in children, 18 and none of these cases were evaluated using molecu- Challenges in physicians' ability to suspect and recognize melanoma in young children may contribute to the "advanced" clinical and histopathologic features of children observed in this study. Pediatric melanoma is commonly misdiagnosed as a benign mimic lesion, 19 and melanoma in younger children is less likely to present with the typical ABCD features (asymmetry, border irregularity, color heterogeneity, diameter >6 mm) than in adolescents. 20 Pediatric melanomas may present as lesions that are amelanotic, that bleed, bumps, that are homogenous in color, and that arise de novo, and these pediatric-specific "ABCDE" detection criteria have been proposed for use in conjunction with typical detection criteria, 20 although a recent study showed that the majority of pediatric melanomas in an international cohort (N = 52) did not meet the modified pediatric ABCDE criteria. Characteristic dermoscopic features were helpful for diagnosis of these malignant lesions. 13 Medical records at this institution did not consistently document ABCDE or dermoscopic features before biopsy, and we are unable to comment on the presence of these features in our cohort. Nevertheless, we recommend careful attention to pediatric and traditional melanoma features, as well as dermoscopic characteristics, when choosing whether to biopsy a suspicious lesion in a child.
Small sample size and acquisition from a single tertiary referral center limited this study. There were no cases of melanoma associated with large or giant congenital melanocytic nevi in the cohort.
This subtype is known to cause disproportionate mortality in very young children, and higher mortality may have been observed if more children with giant congenital melanocytic nevi had been diagnosed at this institution and thus included in this cohort. 12 The only central nervous system melanoma identified in this study was an 18-year-old boy with unclassified melanoma of the brain who had a nevus of Ota. Nevus of Ota has been reported to undergo malignant degeneration in as many as 4.6% of cases, 21 may present a higher risk of malignancy in white individuals, 22 and has been shown to be associated with malignancy in children. 23 Longer follow-up might provide important insights. In a recent population-based review of pediatric melanoma, average time to death after diagnosis was 9.3 years.
11
Despite study limitations, clinical findings observed in this cohort illustrate two important differences in melanoma presenting in childhood than in adolescence. First, spitzoid melanomas appear to be more common in children. Second, melanoma may follow a more aggressive course in adolescents than children.
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